Abstract

Purpose: To investigate the possibility of using oridonin solid lipid nanoparticles (ORI-SLN) as a new kind of drug carrier and examining their anti-tumor effects. Methods: ORI-SLN was prepared by the emulsifying-evaporation method and the particle size, morphology, zeta potential, and entrapment efficiency were studied. The effects of ORI-SLN on the proliferation of B16 cells were investigated by MTT assay. The B16 tumor line was selected to study the anti-tumor effects of ORI-SLN. Results: The results showed that the ORI-SLN were uniform spheres and the encapsulation efficiency was 91.34%. The average size of ORI-SLN was 82.5 nm with a polydispersity index of 0.28 and the zeta potential was –48.2 mv. The MTT test showed that the proliferation of B16 tumor cells in vitro was inhibited by ORI-SLN in a concentration- and time- dependent manner. We found that ORI-SLN had effects on the growth of the B16 tumor line in vivo. Conclusion: The results of this study indicate that ORI-SLN haseffects on the growth of the B16 cell line both in vitro and in vivo.


Keywords:  Oridonin   Solid lipid nanoparticles   Anti-tumor